Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
| Status: | Completed |
|---|---|
| Conditions: | Hepatitis, Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 19 - Any |
| Updated: | 2/8/2018 |
| Start Date: | May 7, 2014 |
| End Date: | May 3, 2017 |
Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
Long Term Observational Extension Study Designed to Monitor Long-Term Efficacy and Safety of
Miravirsen Sodium in Combination with Telaprevir and Ribavirin in Subjects with Chronic
Hepatitis C Virus Genotype 1 Infection
Miravirsen Sodium in Combination with Telaprevir and Ribavirin in Subjects with Chronic
Hepatitis C Virus Genotype 1 Infection
Inclusion Criteria:
- Participated in Study SPC3649-205 (this would include those who completed study
SPC3649-205, those who discontinued or terminated the study early for whatever reason
(including treatment failure) and those who opted to receive approved therapy for the
treatment of HCV infection).
Exclusion Criteria:
- Those unwilling to provide informed consent for participation in this study.
- Subjects who have received investigational drug therapy after discontinuation,
termination, or successful completion of Study SPC3649-205.
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials